Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Therapy
NCT01500200 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Therapy
- Lead sponsor
- Alkermes, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2011
- Completion date
- March 31, 2013
- Enrollment
- 142 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.